721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Abstract

Pre-clinical and clinical data indicate that glucocorticoid receptor (GR) antagonism may enhance/restore chemotherapy sensitivity. This is the first randomized, controlled study to explore the efficacy and safety of relacorilant (RELA), a selective GR modulator, in combination w/ nab-paclitaxel (nab-pac) compared to nab-pac alone.